US stock · Healthcare sector · Biotechnology
Company Logo

Biohaven Pharmaceutical Holding Company Ltd.

BHVNNYSE

151.17

USD
-0.36
(-0.24%)
Market Closed
-11.61P/E
-23Forward P/E
-0.58P/E to S&P500
10.831BMarket CAP
- -Div Yield
Upcoming Earnings
7 Nov-11 Nov
Shares Short
8/31/22
4.43M
Short % of Float
6.87%
Short % of Shares Outs.
6.19%
% Held by Insiders
11.39%
% Held by Institutions
81.59%
Beta
1.04
PEG Ratio
- -
52w. high/low
152.56/79.01
Avg. Daily Volume
0.74M
Return %
Stock
S&P 500
1 year
10.50
(16.20)
3 years
262.17
22.35
5 years
302.79
44.82
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
39.51
17.00
44.28
16.50
67.86
34.06
100.77
26.56
151.51
62.57
152.56
79.01
Currency: USD
- -
- -
- -
- -
- -
- -
- -
- -
- -
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.08
7.87
12.60
Earnings per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.77)
(4.48)
(4.57)
(6.15)
(10.91)
(13.06)
(14.41)
(14.82)
FCF per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.43)
(2.08)
(3.42)
(5.14)
(7.86)
(12.74)
(14.18)
(8.99)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.00
0.00
0.02
0.11
0.08
0.77
0.03
0.84
Book Value per sh.
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.09
1.21
4.74
3.85
(0.15)
(6.65)
(12.59)
(9.49)
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
- -
- -
- -
13
14
28
39
48
59
59
68
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(6.0)
(5.4)
(4.4)
(4.8)
(7.2)
(11.6)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.3)
(0.2)
(0.2)
(0.1)
(0.2)
(0.6)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
64
463
860
Operating margin
- -
- -
- -
- -
- -
- -
- -
- -
- -
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(1,014.3)%
(152.2)%
(84.3)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0
- -
- -
- -
9
25
23
Net profit (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
(10)
(64)
(127)
(241)
(529)
(767)
(847)
(929)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.1)%
(0.8)%
(0.2)%
(0.1)%
(1.3)%
(0.6)%
(6.1)%
Net profit margin
- -
- -
- -
- -
- -
- -
- -
- -
- -
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(1,205.1)%
(183.0)%
(118.3)%
Working capital (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
16
127
253
262
327
342
502
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
118
- -
267
627
765
Equity (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
17
132
151
(7)
(390)
(739)
(801)
ROIC
- -
- -
- -
- -
- -
- -
- -
- -
- -
(598.5)%
(331.5)%
(89.9)%
(84.3)%
(174.6)%
(165.1)%
(146.2)%
(110.3)%
Return on capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
(497.5)%
(233.7)%
(83.4)%
(78.4)%
(140.9)%
(97.4)%
(69.3)%
(53.7)%
Return on equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
(879.5)%
(370.8)%
(96.4)%
(159.6)%
7,122.9%
196.4%
114.5%
116.0%
Plowback ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
5 Aug · 2022 | Q2
All numbers in millions
Total liabilities
$ 2,192
Total assets
$ 1,386
Long-term debt
$ 765
Cash and equiv.
$ 236
Goodwill
$ - -
Retained earnings
$ (3,144)
Common stock
71
Enterprise Value
$ 11,360
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
317
355
365
Receivables
3
120
308
Inventory
- -
40
81
Other
9
(96)
(22)
Current assets
328
603
876
Acc. Payable
14
48
52
Debt due
- -
- -
- -
Other
52
228
483
Current liabilities
66
277
534
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
626.91%
- -
- -
Cash flow
11.29%
77.02%
- -
Earnings
10.41%
66.08%
- -
Dividends
- -
- -
- -
Book value
89.40%
1,289.27%
- -
Insider Trading
Type
Shares
Date
Bailey Gregory
Purchase
38,000
08/19/22
Antonijevic Irina
Award
5,070
05/11/22
Clark George C.
Exempt
2,250
05/10/22
Clark George C.
Sale
4,200
05/10/22
Clark George C.
Exempt
2,250
05/10/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
1
10
18
35
64
2021
44
93
136
190
463
2022
319
215
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(2.94)
(3.08)
(3.32)
(3.71)
(13.06)
2021
(4.51)
(3.59)
(2.93)
(3.39)
(14.41)
2022
(1.65)
(6.21)
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Vlad Coric
Full-time employees:
928
City:
New Haven
Address:
215 Church St
IPO:
May 4, 2017
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases. Its portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have four migraine attacks per month. It is also developing a pipeline of late-stage product candidates across five mechanistic platforms, including CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia; MPO inhibition for amyotrophic lateral sclerosis; and Kv7 Ion Channel Activators (Kv7) for focal epilepsy and neuronal hyperexcitability, as well as myostatin inhibition for neuromuscular diseases. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Recent News
· 10 May, 2022 · The Wall Street Journal